NewAmsterdam Pharma (NAMS) News Today $26.61 +1.90 (+7.69%) (As of 12/17/2024 05:46 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period NewAmsterdam Pharma (NASDAQ:NAMS) Shares Up 4.7% - Time to Buy?NewAmsterdam Pharma (NASDAQ:NAMS) Trading 4.7% Higher - Still a Buy?December 17 at 4:24 PM | marketbeat.comNap B.V. Forgrowth Sells 166,011 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) StockDecember 17 at 4:18 AM | insidertrades.comNewAmsterdam Pharma (NASDAQ:NAMS) Major Shareholder Nap B.V. Forgrowth Sells 166,011 SharesNewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) major shareholder Nap B.V. Forgrowth sold 166,011 shares of the company's stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $25.39, for a total transaction of $4,215,019.29. Following the completion of the sale, the insider now owns 11,150,461 shares of the company's stock, valued at approximately $283,110,204.79. This represents a 1.47 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.December 16 at 4:18 PM | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Enters into Underwriting Agreement for Public OfferingNEW YORK--(BUSINESS WIRE)-- December 13, 2024-- NewAmsterdam Pharma Company N.V. (NAMS) announced today the completion of an underwritten public offering involvinDecember 15 at 2:33 AM | americanbankingnews.comNewAmsterdam Pharma (NASDAQ:NAMS) Price Target Raised to $47.00December 14, 2024 | americanbankingnews.comNewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters' Option to Purchase Additional SharesDecember 13, 2024 | globenewswire.comNewAmsterdam Pharma (NASDAQ:NAMS) Sees Large Volume Increase - Here's What HappenedNewAmsterdam Pharma (NASDAQ:NAMS) Sees Unusually-High Trading Volume - Here's WhyDecember 13, 2024 | marketbeat.comNewAmsterdam Pharma’s $452.6M Public Offering SuccessDecember 13, 2024 | tipranks.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $3.97 Million Holdings in NewAmsterdam Pharma (NASDAQ:NAMS)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 1,231.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 239,December 13, 2024 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Shares Acquired by Fmr LLCFmr LLC boosted its holdings in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 35.6% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 330,412 shares of the company's stock after purchasing an additional 86,712 shares duringDecember 13, 2024 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Reaches New 52-Week High on Analyst UpgradeDecember 13, 2024 | americanbankingnews.comNewAmsterdam Pharma Soars 41% On A Surprise Benefit From Cholesterol DrugDecember 12, 2024 | msn.comNewAmsterdam Pharma Stock Hits 90-Plus RS RatingDecember 12, 2024 | yahoo.comNewAmsterdam Pharma price target raised to $47 from $35 at ScotiabankDecember 12, 2024 | markets.businessinsider.comNewAmsterdam Pharma prices $416M stock offeringDecember 12, 2024 | seekingalpha.comNewAmsterdam Pharma Co NV Announces Pricing of Public OfferingDecember 12, 2024 | gurufocus.comNewAmsterdam Pharma 12.12M share Secondary priced at $24.50December 11, 2024 | tipranks.comNewAmsterdam Pharma Co NV Announces Pricing of Public OfferingDecember 11, 2024 | gurufocus.comNewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded WarrantsDecember 11, 2024 | globenewswire.comNewAmsterdam Pharma: Positive Obicetrapib Data Leads To New CatalystsDecember 11, 2024 | seekingalpha.comNewAmsterdam Pharma: Positive Obicetrapib Data Leads To New CatalystsDecember 11, 2024 | seekingalpha.comEsperion selloff continues following competitor data from NewAmsterdamDecember 11, 2024 | tipranks.comNewAmsterdam Pharma announces $300M offering of ordinary shares, warrantsDecember 11, 2024 | markets.businessinsider.comNewAmsterdam Pharma Co NV Announces $300 Million Public OfferingDecember 10, 2024 | gurufocus.comNewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded WarrantsDecember 10, 2024 | globenewswire.comVerve Therapeutics has positive read from NewAmsterdam data, says StifelDecember 10, 2024 | tipranks.comNewAmsterdam Pharma price target raised to $48 from $45 at LeerinkDecember 10, 2024 | tipranks.comWhy Is NewAmsterdam Pharma Stock Trading Higher On Tuesday?December 10, 2024 | benzinga.comNewAmsterdam Pharma Soars 41% On An Surprise Benefit From Cholesterol DrugDecember 10, 2024 | yahoo.comNewAmsterdam Pharma Says Main Goal In Phase 3 BROADWAY Study Achieved; Stock Up In Pre-marketDecember 10, 2024 | markets.businessinsider.comNewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial HypercholesterolemiaDecember 10, 2024 | globenewswire.comNewAmsterdam Pharma (NASDAQ:NAMS) Stake Lifted by Frazier Life Sciences Management L.P.Frazier Life Sciences Management L.P. raised its holdings in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 5.1% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,855,194 shares of theDecember 10, 2024 | marketbeat.comJanus Henderson Group PLC Has $25.61 Million Position in NewAmsterdam Pharma (NASDAQ:NAMS)Janus Henderson Group PLC raised its holdings in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 51.1% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,540,729 shares of the company's stock after acquiring an additional 520,772December 7, 2024 | marketbeat.comWalleye Capital LLC Takes $779,000 Position in NewAmsterdam Pharma (NASDAQ:NAMS)Walleye Capital LLC bought a new stake in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 46,947 shares of the company's stock, valued at approximately $779,000. WallDecember 7, 2024 | marketbeat.comStrong Buy Rating for NewAmsterdam Pharma Based on Anticipated Success of BROADWAY Trial and Efficacy of ObicetrapibDecember 6, 2024 | markets.businessinsider.comNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 6, 2024 | globenewswire.comForecasting The Future: 5 Analyst Projections For NewAmsterdam PharmaDecember 5, 2024 | benzinga.comReadystate Asset Management LP Acquires Shares of 121,000 NewAmsterdam Pharma (NASDAQ:NAMS)Readystate Asset Management LP bought a new position in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 121,000 shares of the company's stDecember 5, 2024 | marketbeat.comParkman Healthcare Partners LLC Cuts Stock Position in NewAmsterdam Pharma (NASDAQ:NAMS)Parkman Healthcare Partners LLC decreased its stake in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 22.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 105,334 shares of the company's stock after sellinDecember 4, 2024 | marketbeat.comCinctive Capital Management LP Increases Stock Position in NewAmsterdam Pharma (NASDAQ:NAMS)Cinctive Capital Management LP increased its position in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 77.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 66,571 shares of the company's stock after buying an addiDecember 4, 2024 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Shares Purchased by ArrowMark Colorado Holdings LLCArrowMark Colorado Holdings LLC raised its stake in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 19.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 354,975 shares of the company's stock afDecember 3, 2024 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Receives Average Rating of "Buy" from AnalystsShares of NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) have been assigned an average recommendation of "Buy" from the six research firms that are currently covering the company, Marketbeat.com reports. Six analysts have rated the stock with a buy rating. The average 1-year price target amonDecember 1, 2024 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Shares Down 2.7% - What's Next?NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price Down 2.7% - Here's WhyNovember 29, 2024 | marketbeat.comAnalysts Conflicted on These Healthcare Names: NewAmsterdam Pharma Company (NAMS) and Roche Holding AG (OtherRHHVF)November 25, 2024 | markets.businessinsider.comJennison Associates LLC Buys 83,115 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)Jennison Associates LLC increased its stake in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 8.9% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,020,278 shares of the company's stock after purchasing an additional 83November 23, 2024 | marketbeat.comRBC Capital Sticks to Their Buy Rating for NewAmsterdam Pharma Company (NAMS)November 22, 2024 | markets.businessinsider.comNewAmsterdam Pharma's (NAMS) "Buy" Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and set a $36.00 target price on shares of NewAmsterdam Pharma in a research report on Thursday.November 21, 2024 | marketbeat.comBuy Rating for NewAmsterdam Pharma Amid Promising TANDEM Trial Results and Upcoming BROADWAY Trial ExpectationsNovember 20, 2024 | markets.businessinsider.comNewAmsterdam Pharma Phase 3 Drug Combo Study Hits Main EndpointsNovember 20, 2024 | marketwatch.comNewAmsterdam Announces Positive Data From Phase 3 Trial Evaluating Obicetrapib+EzetimibeNovember 20, 2024 | markets.businessinsider.com Get NewAmsterdam Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NAMS and its competitors with MarketBeat's FREE daily newsletter. Email Address DeFi Coin on Verge of Breakout! (Ad)[FREE BOOK] Can You Make a Fortune in Crypto with $50? Get started now before the market takes off! Click here to request your free copy NOW! NAMS Media Mentions By Week NAMS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NAMS News Sentiment▼0.730.71▲Average Medical News Sentiment NAMS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NAMS Articles This Week▼263▲NAMS Articles Average Week Get NewAmsterdam Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NAMS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Intra-Cellular Therapies News Roivant Sciences News Ascendis Pharma A/S News Revolution Medicines News Lantheus News Nuvalent News Legend Biotech News Blueprint Medicines News Elanco Animal Health News Cytokinetics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NAMS) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewAmsterdam Pharma Please log in to your account or sign up in order to add this asset to your watchlist. Share NewAmsterdam Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
